Jim C. Hu, MD, MPH, presented “Overview of Image-Guided, Minimally-Invasive Focal Treatment” during the Virtual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer in October 2020.
How to cite: Hu, Jim C. “Overview of Image-Guided, Minimally-Invasive Focal Treatment.” October 2020. Accessed Dec 2024. https://dev.grandroundsinurology.com/overview-of-image-guided-minimally-invasive-focal-treatment/
Overview of Image-Guided, Minimally-Invasive Focal Treatment – Summary
Jim C. Hu, MD, MPH, Director of the LeFrak Center for Robotic Surgery and the Ronald P. Lynch Chair in Urologic Oncology at Weill Cornell Medical College, reviews emerging data on patient selection and outcomes of focal therapy. He discusses results of recent studies examining high-intensity focused ultrasound (HIFU) and comparing it with cryoablation, and looks at cancer recurrence rates after focal therapy. Dr. Hu describes an exploratory study of in-office partial gland cryoablation, then discusses a current project, PC CONCEPT, which is evaluating focal therapy at a population level. He emphasizes that a significant number of men do not get a prostate biopsy during follow-up. Since 30-60% of men who do receive a follow-up biopsy are shown to have biopsy-proven cancer, there is concern that men who do not receive a biopsy at some point following treatment may have recurrent cancer and have missed a window of curability. Dr. Hu concludes by noting that functional outcome preservation is better with focal therapy than radical prostatectomy, with only a 1-2% risk of significant deterioration of urinary and sexual functioning. He also adds that volume and orientation changes after focal therapy can create significant challenges for accurate biopsy and surveillance.
The Virtual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer brings together key international opinion leaders of every clinical subspecialty involved in patient care. This event is an integral part of the AdMeTech Foundation’s Annual Summit, which was established in 2016 and become seminal in shaping the state of the art and future vision for precision care. The goal of this event is three-fold: 1) Educating the key stakeholders; 2) Supporting a sustained cross-disciplinary dialogue and consensus on the best emerging clinical practices and research priorities; and 3) Expediting clinical adoption of promising novel diagnostics and therapeutics. For more educational activities from this virtual event, visit our collection page.
ABOUT THE AUTHOR
Jim C. Hu, MD, MPH, serves as the Director of the LeFrak Center for Robotic Surgery and the Ronald P. Lynch Chair in Urologic Oncology at Weill Cornell Medical College. He is a urologic oncologist specializing in image-guided diagnosis and treatment of prostate cancer and is also an attending urologist at NewYork-Presbyterian Hospital. Dr. Hu received his Master’s in Public Health in Health Policy and Management from Johns Hopkins University and his Medical Degree from Baylor College of Medicine. Dr. Hu then completed his Urology Residency at the David Geffen School of Medicine at UCLA and his Urologic Oncology Fellowship at City of Hope National Medical Center. He served as Director of Robotic and Minimally Invasive Surgery at Brigham and Women’s Hospital of Harvard Medical School. He was then recruited to UCLA, where he was the Henry Singleton Chair of Robotic and Minimally Invasive Surgery before joining the faculty at Weill Cornell Medical College in 2015. His comparative effectiveness research interests have been funded by federal and foundation sources. He has authored 240+ peer-reviewed papers and has performed thousands of robot-assisted prostatectomies, among over 3500 laparoscopic, robotic, and open procedures.
